AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21546942
Drug: Probiotic-supplemented feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic-supplemented feeding (Lactobacillus rhamnosus GG and Bifidobacterium infantis added to enteral feeding, continued once daily until discharge or 34 weeks PMA)
Trial: 20423755
Drug: Oral high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high-dose dexamethasone
Trial: 20423755
Drug: Daily high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily high-dose prednisolone
Trial: 18922117
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by hormonal therapy
Trial: 15797962
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) and luteinizing hormone releasing hormone analog (LHRHa)
Trial: 12206636
Drug: Various dose
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various dose fractionation schedules for breast cancer radiotherapy
Trial: 12412823
Drug: Zolmitriptan nasal
RxNorm normalized name: Zolmitriptan Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan nasal spray 1 mg
Trial: 8594954
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg fentanyl, sodium thiopental, succinylcholine 1 mg/kg
Trial: 8594954
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg fentanyl and propofol (demand-adapted)
Trial: 8594954
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg fentanyl and propofol (demand-adapted)
Trial: 8594954
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg fentanyl, propofol, succinylcholine 1 mg/kg
Trial: 26299229
Drug: Nesiritide treatment
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nesiritide treatment
Trial: 26299229
Drug: Diuretic response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Diuretic response (weight loss per 40 mg of furosemide)
Trial: 26299229
Drug: Diuretic response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Diuretic response (good responders)
Trial: 26299229
Drug: Diuretic response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Diuretic response based on urine output per 40 mg of furosemide
Trial: 25659828
Drug: Adjunctive zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive zonisamide
Trial: 17911992
Drug: Retapamulin ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retapamulin ointment, 1% (twice daily for 5 days)
Trial: 17911992
Drug: Sodium fusidate
RxNorm normalized name: Sodium fusidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium fusidate ointment, 2% (3 times daily for 7 days)
Trial: 9084888
Drug: Rectal suppository
RxNorm normalized name: Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal suppository containing ozagrel tablet
Trial: 9084888
Drug: Oral ozagrel
RxNorm normalized name: Ozagrel
DrugBank: Ozagrel (DB12017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ozagrel tablet
Trial: 8125395
Drug: Enteral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutritional support in conjunction with radiotherapy or chemotherapy
Trial: 3234516
Drug: Turbuhaler (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler (multiple dose powder inhaler)
Trial: 29315168
Drug: Aerobic training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic training regimen of 72 supervised treadmill walking sessions delivered thrice weekly for 24 consecutive weeks
Trial: 19114389
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA supplements and low n-6 PUFA cooking oils and spreads
Trial: 10978947
Drug: Bismuth-based treatment
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based treatment (colloidal bismuth subcitrate 120 mg qid plus metronidazole 250 mg qid plus tetracycline 500 mg qid)
Trial: 10978947
Drug: Bismuth-based treatment
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based treatment
Trial: 1442450
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg, 2x/day)
Trial: 31602573
Drug: AG200‐15 patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200‐15 patch (N=78)
Trial: 31602573
Drug: Xulane patch
RxNorm normalized name: Xulane
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xulane patch (N=77)
Trial: 28949010
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral micronized progesterone, six-hourly, starting at 14-18 weeks until 37 weeks or delivery
Trial: 22024310
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 mg oral on day 1, 10 mg/day oral on days 2-4) with palonosetron (0.25 mg IV) and dexamethasone (20 mg IV)
Trial: 22024310
Drug: Aprepitant (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (125 mg oral on day 1, 80 mg oral on days 2-3) with palonosetron (0.25 mg IV) and dexamethasone (12 mg IV)
Trial: 2661606
Drug: Amantadine 200
RxNorm normalized name: amantadine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 200 mg/day
Trial: 11886025
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral therapy (CBT), 16 sessions
Trial: 7616988
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg zidovudine immediately
Trial: 7616988
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg zidovudine immediately
Trial: 7616988
Drug: Deferred therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred therapy (placebo until CD4 < 500)
Trial: 31376908
Drug: Rivaroxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (15 mg daily)
Trial: 18620849
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intra-nasal midazolam
Trial: 1941407
Drug: Bovine milk
RxNorm normalized name: Bovine Milk Plasma
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine milk protein preparation (BMP)
Trial: 29933530
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine comprehensive therapy
Trial: 29933530
Drug: Modern Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern Western Medicine treatment
Trial: 10757273
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (200 mg)
Trial: 10757273
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (200 mg)
Trial: 20964499
Drug: Moclobemide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300 mg/day)
Trial: 9023788
Drug: Fluoxetine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (200 mg/day)
Trial: 1890934
Drug: Purified sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified sulfur (0.5-1 g mixed with 0.25 g of glucose, administered every 2-3 hours before irradiation)
Trial: 6410897
Drug: Acidophilus milk
RxNorm normalized name: ACIDOPHILUS
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidophilus milk (240 ml, three times a day for 2 weeks)
Trial: 29960810
Drug: Probiotic (PR)
RxNorm normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (PR) group received a probiotic formulation containing Bifidobacterium breve BR03 and B. breve B632 for 3 months.
Trial: 29960810
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) group, received no active treatment.
Trial: 27323614
Drug: Compound Sodium
RxNorm normalized name: SODIUM CHLORIDE 6 g in 1 L / SODIUM LACTATE 3.22 g in 1 L / POTASSIUM CHLORIDE 400 mg in 1 L / CALCIUM CHLORIDE 270 mg in 1 L INTRAVENOUS INJECTION, SOLUTION [COMPOUND SODIUM LACTATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Sodium Chloride Injection (Control)
Trial: 25137874
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 to 320 mg/day (n = 18)
Trial: 25137874
Drug: Non-renin-angiotensin-aldosterone-system blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-renin-angiotensin-aldosterone-system blocking antihypertensive agents (control, n = 15)
Trial: 20146169
Drug: Atorvastatin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin, 20 mg daily
Trial: 20146169
Drug: Simvastatin, 20
RxNorm normalized name: Simvastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 20 mg daily
Trial: 17909315
Drug: Subunit-boosted vaccine
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit-boosted vaccine
Trial: 17909315
Drug: ogp160-boosted vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ogp160-boosted vaccine
Trial: 17909315
Drug: gp120 B/E-boosted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp120 B/E-boosted vaccine
Trial: 16184581
Drug: Caffeine 400
RxNorm normalized name: caffeine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 400 mg administered 30 min prior to sleep
Trial: 16184581
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered prior to sleep
Trial: 22677762
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of insulin
Trial: 22677762
Drug: Frequent (every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent (every 3h) subcutaneous injections of insulin
Trial: 11817991
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment with concomitant benazepril therapy
Trial: 11817991
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment without benazepril
Trial: 8785399
Drug: Cyclosporine (CsA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA; 4 to 5 mg/kg per day)
Trial: 8785399
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 to 30 mg daily)
Trial: 6222756
Drug: I% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I% metronidazole cream
Trial: 9377615
Drug: Placebo (cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cream base)
Trial: 29121350
Drug: Individualized FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized FSH dosing (450/225 IU for RCT1, 100 IU for RCT2)
Trial: 29121350
Drug: Standard FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard FSH dosing (150 IU)
Trial: 29121350
Drug: Individualized FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized FSH dosing
Trial: 25639994
Drug: STEP (Specialized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STEP (Specialized Treatment Early in Psychosis)
Trial: 17690015
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group 2).
Trial: 6115730
Drug: Propranolol 10
RxNorm normalized name: propranolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 10 mg
Trial: 2347652
Drug: Org 10172
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 10172 administered as a single intravenous bolus of 2400 anti‐Xa units at start of dialysis
Trial: 2347652
Drug: Org 10172
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 10172 administered as a single bolus of 3200 anti‐Xa units at start of dialysis
Trial: 2347652
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (3250‐4750 I.U. heparin at start of hemodialysis followed by continuous infusion of 2000‐2700 I.U. per hour)
Trial: 2347652
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including Org 10172 and heparin)
Trial: 486891
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of 60 ml of sodium iothalamate 70%
Trial: 486891
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of a larger dose of contrast agent
Trial: 25453380
Drug: Frozen Hoodia
RxNorm normalized name: HOODIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frozen Hoodia (3 g)
Trial: 17561009
Drug: Oral norethisterone
RxNorm normalized name: ethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral norethisterone acetate 1 mg/day + 17beta-estradiol 2 mg/day
Trial: 15709712
Drug: Allogeneic irradiated
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic irradiated RCC-cell-line cells (ACHN-IL-2) admixed with autologous metastatic formalin-treated tumour cells, administered subcutaneously, 4-20 injections (mean 10 +/- 4), average of 92 x 10(6) ACHN-IL-2 transfected cells.
Trial: 15709712
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving standard immunotherapy without the vaccine.
Trial: 8273793
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg/day continuously for 5 years (Group A)
Trial: 8273793
Drug: Seasonal prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal prophylactic treatment with ranitidine 300 mg/day for 8 weeks in spring and fall (Group B)
Trial: 3054641
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) - one swallow tablet 4 times a day (11 patients)
Trial: 3054641
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) - two swallow tablets twice daily (16 patients)
Trial: 3054641
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) - two buffered swallow tablets twice daily (14 patients)
Trial: 3054641
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) - two chew tablets twice daily (22 patients)
Trial: 3054641
Drug: Patients rebiopsied
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients rebiopsied 44‐137 days following treatment
Trial: 19954715
Drug: Equasym Retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equasym Retard 20 mg
Trial: 19954715
Drug: Medikinet retard
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medikinet retard 20 mg
Trial: 17406138
Drug: Enuretic alarm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enuretic alarm therapy (group 1)
Trial: 17406138
Drug: Desmopressin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin therapy (group 2)
Trial: 17406138
Drug: Enuretic alarm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enuretic alarm therapy as secondary treatment (group 3)
Trial: 14993506
Drug: High dialysis
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dialysis dose (HDD) group (target Kt/V(eq) of 1.4)
Trial: 14993506
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein (HP) diet (1.3 g/kg of ideal body weight/day)
Trial: 14993506
Drug: Regular protein
RxNorm normalized name: PROTEIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular protein (RP) diet (0.9 g/kg/day)
Trial: 14993506
Drug: High dialysis
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dialysis dose (HDD) group
Trial: 14993506
Drug: Regular dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dialysis dose (RDD) group
Trial: 14993506
Drug: Increasing dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing dialysis dose
Trial: 12144582
Drug: Famotidine 10
RxNorm normalized name: famotidine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 10 mg
Trial: 9258137
Drug: 200 mcg
RxNorm normalized name: CrM 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg oral desmopressin
Trial: 9258137
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg oral desmopressin
Trial: 9258137
Drug: 600 mcg
RxNorm normalized name: Biotin 600 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mcg oral desmopressin
Trial: 25977408
Drug: 4-mg nicotine
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg nicotine lozenges
Trial: 20059357
Drug: Tetravalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent dengue vaccine (TDV), 3 injections at months 0, 4, and 12-15
Trial: 20059357
Drug: Tetravalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent dengue vaccine (TDV), 2 injections at months 4 and 12-15
Trial: 20059357
Drug: Tetravalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent dengue vaccine (TDV)
Trial: 15679762
Drug: Mesalazine pellets
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine pellets (1.5 g/day in three doses)
Trial: 15679762
Drug: Mesalazine tablets
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine tablets (1.5 g/day in three doses)
Trial: 10225572
Drug: 500 mg/10
RxNorm normalized name: amikacin 500 mg/100 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/10 mL oral suspension
Trial: 10225572
Drug: 500 mg/10
RxNorm normalized name: amikacin 500 mg/100 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/10 mL suspension (fasted)
Trial: 10225572
Drug: 500 mg/5
RxNorm normalized name: Liquid C, 500 mg/5 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/5 mL suspension (fasted)
Trial: 10225572
Drug: 500 mg/10
RxNorm normalized name: amikacin 500 mg/100 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/10 mL suspension (fed)
Trial: 2245092
Drug: Ibuprofen-codeine combination
RxNorm normalized name: codeine / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen-codeine combination
Trial: 639430
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg piretanide
Trial: 26228672
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atorvastatin 40 mg and ezetimibe 10 mg
Trial: 26228672
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (PS) added to atorvastatin therapy
Trial: 26228672
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (PS) added to combined therapy
Trial: 20046230
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet therapy (aspirin 100 mg)
Trial: 20046230
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antiplatelet and anticoagulation therapy (target INR: 2.0‐3.0; mean 2.4+/‐0.3)
Trial: 29330312
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet therapy (aspirin)
Trial: 11405833
Drug: High-intensity laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity laser treatment